Entera Bio (ENTX) grants director 20,034 shares and 40,000 options
Rhea-AI Filing Summary
Entera Bio Ltd. director Sean Ellis reported equity compensation awards. He received 20,034 ordinary shares in lieu of cash board fees for the first and second quarters of 2026, after Board approval and a Form S-8 filed on August 7, 2026. He was also granted fully vested options for 40,000 ordinary shares at an exercise price of $1.37 per share, approved earlier in 2026 subject to shareholder approval and the same Form S-8. After these grants, he directly owns 208,132 ordinary shares and holds options for 40,000 shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 20,034 shares
Net Buy
2 txns
Insider
Ellis Sean
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) F2 | 40,000 | $0.00 | $0.00 |
| Grant/Award | Ordinary Shares, par value NIS 0.0000769 per share F1 | 20,034 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 40,000 shares (Direct);
Ordinary Shares, par value NIS 0.0000769 per share — 208,132 shares (Direct)
Footnotes (2)
- F1. The Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Person in lieu of the cash fees the Reporting Person was entitled to for services rendered as a director of the Company for the first quarter and second quarter of 2026. This grant of shares was approved by the Board on August 5, 2026, subject to the filing by the Company of a Registration Statement on Form S-8 registering the shares, which occurred on August 7, 2026.
- F2. Represents a grant of fully vested options to purchase ordinary shares. This grant of options was approved by the Board on May 7, 2026, subject to (i) approval by the Company's shareholders, which was obtained on July 14, 2026 and (ii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026.
Key Figures
Ordinary shares granted: 20,034 shares
Stock options granted: 40,000 options
Exercise price: $1.37 per share
+3 more
6 metrics
Ordinary shares granted
20,034 shares
Shares awarded in lieu of cash director fees for Q1 and Q2 2026
Stock options granted
40,000 options
Fully vested options to purchase ordinary shares granted to director Sean Ellis
Exercise price
$1.37 per share
Exercise price of options to purchase ordinary shares
Option expiration
May 7, 2036
Expiration date of options granted to Sean Ellis
Shares owned after grant
208,132 shares
Sean Ellis direct ordinary share holdings following the reported share grant
Transaction date
August 7, 2026
Date for reported share and option awards to Sean Ellis
Key Terms
Registration Statement on Form S-8, fully vested options, ordinary shares
3 terms
Registration Statement on Form S-8 regulatory
"subject to the filing by the Company of a Registration Statement on Form S-8 registering the shares"
A registration statement on Form S-8 is the U.S. Securities and Exchange Commission filing companies use to register shares they intend to grant to employees, directors, consultants or benefit plans under stock compensation programs. It matters to investors because it signals potential issuance of new shares tied to pay and incentives, which can increase the total shares outstanding — like adding more slices to a pie — reducing each existing share’s ownership and potentially affecting earnings per share and stock value.
fully vested options financial
"Represents a grant of fully vested options to purchase ordinary shares."
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transactions did Entera Bio (ENTX) director Sean Ellis report?
Sean Ellis reported two equity compensation awards: a grant of 20,034 ordinary shares and fully vested options for 40,000 ordinary shares. Both awards were approved by the Board and became effective after related shareholder and Form S-8 conditions were satisfied.
What are the terms of Sean Ellis’s Entera Bio (ENTX) stock options?
Ellis was granted fully vested options for 40,000 ordinary shares with an exercise price of $1.37 per share and an expiration date of May 7, 2036. The grant was approved in May 2026, subject to shareholder approval and a Form S-8 filing.
Were Sean Ellis’s Entera Bio (ENTX) equity awards tied to a Form S-8 registration?
Yes. Both the 20,034-share grant and the 40,000-share option grant were expressly conditioned on the Company filing a Registration Statement on Form S-8 to register the relevant shares, which the company states occurred on August 7, 2026.